BioCentury
ARTICLE | Company News

BMS expands R&D collaboration with Tsinghua

July 27, 2018 6:43 PM UTC

Bristol-Myers Squibb Co. (NYSE:BMY) and Tsinghua University expanded a 2012 deal to include identification and validation of new targets in autoimmune diseases and cancer, as well as for discovery of candidates for clinical development. BMS has an option to license exclusive rights to compounds discovered by the university. Financial terms were not disclosed.

The 2012 deal focused on discovery and 3D mapping of autoimmune targets and structural biology research...